Late Breaking Abstract Parallel Session 3
Nov
2026
Description
Discover and learn more about the latest advancement and breakthroughs in hepatology that are shaping the future of liver disease.
Presentations
10:30 AM
- 10:45 AM
Convention Center - General Session, Hall A
Efficacy and Safety of Pemvidutide in the Treatment of Adults with Alcohol Use Disorder: Results from RECLAIM, a 24-Week Phase 2 Randomized Double-Blind Placebo-Controlled Trial
Henry R Kranzler, MD | Abstract Presenter
10:45 AM
- 11:00 AM
Convention Center - General Session, Hall A
DR10624, a First-In-Class, FGF21 Receptor/Glucagon Receptor/GLP-1 Receptor Triple Agonist, Rapidly and Significantly Reduced Liver Fat and Fibrosis Markers, and Improved Liver Functions and Lipid Profiles, in Patients With MASLD/MASH: Results of a Randomized Phase 2 Trial.
Vincent WS Wong, MD, | Abstract Presenter
11:00 AM
- 11:15 AM
Convention Center - General Session, Hall A
A Phase 2b Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis and Stage 2-3 Fibrosis
Jörn M Schattenberg, MD, | Abstract Presenter
11:15 AM
- 11:30 AM
Convention Center - General Session, Hall A
A single VRON-0200 dose alone produced durable and/or continuing HBsAg declines, without rebound, for more than two years: complete long-term follow-up results
Grace Lai-Hung Wong, MD, , MBChB(Hons), MD, FRCP(Lond, Edin), FHKCP, FH | Abstract Presenter
11:30 AM
- 11:45 AM
Convention Center - General Session, Hall A
Elebsiran plus BRII-179 and peginterferon alfa achieve greater HBsAg loss and enhanced immune responses compared with peginterferon alfa alone in virologically suppressed chronic hepatitis B: Results from the Phase 2 ENHANCE Part A-1
David Margolis | Abstract Presenter
11:45 AM
- 12:00 PM
Convention Center - General Session, Hall A
RNA editing for the treatment of alpha-1 antitrypsin deficiency (AATD): interim results from RestorAATion-2
Pavel Strnad | Abstract Presenter
